
In a CDC press briefing, experts said the vaccine’s single-dose approach will enable more mobile units and pop-up events to vaccinate hard-to-reach populations.

Aislinn Antrim is managing editor at Pharmacy Times®. She graduated from the University of North Carolina at Chapel Hill in 2019 and received her master’s in communication and media at Rutgers University in 2023.

In a CDC press briefing, experts said the vaccine’s single-dose approach will enable more mobile units and pop-up events to vaccinate hard-to-reach populations.

Cost-conscious guidelines, government regulation, market-level incentives can ensure access, help patients save money.

Education and keeping up with the latest literature are 2 of the biggest challenges in treating venous thromboembolism.

Data from the FIGHT trial suggests that approximately 30% of patients with non-human epidermal growth factor 2-positive GEJ cancers overexpress fibroblast growth factor receptor 2.

Study findings suggest that many individuals who report peanut allergies and experience potentially severe allergic reactions are not obtaining clinical diagnosis of their allergies.

The efficacy results demonstrated that there were 4 patients with confirmed partial response, and an additional 3 patients had stable disease lasting 16 weeks or longer.

The program educates patients on how to use the FreeStyle Libre 2 system as well as ways to positively impact their glucose levels through diet and fitness.

As experts seek to minimize hospitalizations during flu season and a pandemic, reformulated dapsone could offer a cost-effective solution.

Patients with HIV who were hospitalized with COVID-19 were found to have high proportions of HIV virologic control on antiretroviral therapy.

Panel of experts discusses alert systems, PPE, and surface contamination as methods for minimizing exposure to dispensing pharmacists

During this study, no patient receiving TDF and FTC was admitted to intensive care or died.

A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.

Uncontrolled hypertension is the largest modifiable risk factor contributing to death from all causes in the United States.